These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830 [TBL] [Abstract][Full Text] [Related]
3. Treating intraocular inflammatory disease in the 21st century. Nussenblatt R Arch Ophthalmol; 2005 Jul; 123(7):1000-1. PubMed ID: 16009844 [No Abstract] [Full Text] [Related]
4. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease. Morris DS; Gavin MP; Sturrock RD Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763 [No Abstract] [Full Text] [Related]
5. Optimizing the use of tumor necrosis factoralpha inhibitors in refractory uveitis. Sebastian RT; Harding SP; Bucknall RC; Pearce IA Arch Ophthalmol; 2006 Oct; 124(10):1505; author reply 1505-6. PubMed ID: 17030729 [No Abstract] [Full Text] [Related]
6. The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis. Demir T; Gödekmerdan A; Balbaba M; Türkçüoglu P; Ilhan F; Demir N Indian J Ophthalmol; 2006 Dec; 54(4):241-5. PubMed ID: 17090875 [TBL] [Abstract][Full Text] [Related]
7. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Suhler EB; Smith JR; Giles TR; Lauer AK; Wertheim MS; Kurz DE; Kurz PA; Lim L; Mackensen F; Pickard TD; Rosenbaum JT Arch Ophthalmol; 2009 Jun; 127(6):819-22. PubMed ID: 19506209 [No Abstract] [Full Text] [Related]
9. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis. Lee RW; Dick AD Br J Ophthalmol; 2010 Mar; 94(3):269-70. PubMed ID: 20215370 [No Abstract] [Full Text] [Related]
10. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Farvardin M; Afarid M; Mehryar M; Hosseini H Retina; 2010 Oct; 30(9):1530-5. PubMed ID: 20924267 [TBL] [Abstract][Full Text] [Related]
11. Uncovering the risks of immunosuppressive therapy in patients with uveitis. Goldstein DA Arch Ophthalmol; 2009 Jun; 127(6):799-800. PubMed ID: 19506201 [No Abstract] [Full Text] [Related]
12. [Medium-long term treatment with infliximab and methotrexate in posterior and/or chronic uveitis refractory to conventional treatment]. Cobo-Ibáñez T; Muñoz-Fernández S; Hidalgo-Barrero V; Martín-Mola E Med Clin (Barc); 2006 Jan; 126(1):34-5. PubMed ID: 16409950 [No Abstract] [Full Text] [Related]
14. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571 [TBL] [Abstract][Full Text] [Related]
15. Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLA-B27-related uveitis. Papadia M; Herbort CP Ocul Immunol Inflamm; 2010 Dec; 18(6):482-4. PubMed ID: 20735341 [TBL] [Abstract][Full Text] [Related]
16. Infliximab and adalimumab for uveitis. Martel JN; Esterberg E; Nagpal A; Acharya NR Ocul Immunol Inflamm; 2012 Feb; 20(1):18-26. PubMed ID: 22324897 [TBL] [Abstract][Full Text] [Related]
17. Infliximab in the treatment of refractory posterior uveitis. Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408 [TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389 [TBL] [Abstract][Full Text] [Related]
19. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907 [TBL] [Abstract][Full Text] [Related]
20. Cutting-edge issues in autoimmune uveitis. Levy RA; de Andrade FA; Foeldvari I Clin Rev Allergy Immunol; 2011 Oct; 41(2):214-23. PubMed ID: 21913066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]